Carna Biosciences, Inc. (TYO:4572)
Japan flag Japan · Delayed Price · Currency is JPY
300.00
-6.00 (-1.96%)
Aug 1, 2025, 3:30 PM JST

Carna Biosciences Company Description

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan.

Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels.

The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays.

It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable small molecule inhibitor of CDC7 kinase that is in preclinical trials to treat cancer; AS-0871, a small molecule drug for inflammatory and immune disorders, which is in Phase 1 clinical trials; and AS-1763, an orally bioavailable and non-covalent inhibitor for the treatment of chronic lymphocytic leukemia and other B cell malignancies that is in preclinical trials.

The company has collaborations with Sumitomo Pharma, Gilead Sciences. Carna Biosciences, Inc. was incorporated in 2003 and is based in Kobe, Japan.

Carna Biosciences, Inc.
CountryJapan
Founded2003
IndustryBiotechnology
SectorHealthcare
Employees63
CEOKohichiro Yoshino

Contact Details

Address:
BMA, 1-5-5 Minatojima-Minamimachi
Kobe, 650-0047
Japan
Phone81 78 302 7039
Websitecarnabio.com

Stock Details

Ticker Symbol4572
ExchangeTokyo Stock Exchange
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyJPY
ISIN NumberJP3220550002
SIC Code2835

Key Executives

NamePosition
Kohichiro YoshinoChief Executive Officer
Emi YamamotoChief Financial Officer